Korjuny

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody presented as a solution for intraperitoneal injection for use in patients with malignant ascites linked to EpCAM‑positive carcinomas. Approved in the European Union, it is administered under prescription to target tumor cells within the peritoneal cavity, helping to control fluid buildup and disease progression.

GNH USA supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company ensures quality compliance and reliable cold‑chain logistics for biologic products.

Korjuny (catumaxomab) is employed as a targeted immunotherapy for the treatment of malignant ascites that develop in patients with EpCAM‑positive carcinomas, particularly when conventional drainage methods are insufficient. - Malignant ascites associated with EpCAM‑positive carcinomas: reduces peritoneal fluid accumulation and improves symptomatic relief. - Recurrent malignant ascites: offers an additional therapeutic option when standard paracentesis fails. - Peritoneal metastasis‑associated ascites: contributes to local immune‑mediated tumor control.

Common Side Effects: - Fever: transient elevation of body temperature after infusion. - Abdominal pain: mild to moderate discomfort in the peritoneal region. - Nausea or vomiting: gastrointestinal upset following administration. - Diarrhea: loose stools occurring within days of treatment. - Chills or rigors: shaking sensations during or after infusion. - Hypotension: temporary drop in blood pressure during administration.

Serious or Rare Side Effects: - Cytokine release syndrome: severe systemic inflammatory response requiring immediate medical attention. - Hepatic toxicity: elevated liver enzymes or liver dysfunction. - Severe allergic reactions: anaphylaxis or angioedema. - Sepsis-like syndrome: infection‑like symptoms with high fever and organ involvement. - Cardiac arrhythmias: irregular heart rhythms observed during infusion.

Precautions should be taken to monitor patient safety and product integrity. - Monitor for cytokine release syndrome: observe vital signs and laboratory parameters during and after infusion. - Assess liver function: obtain baseline and periodic hepatic enzyme tests. - Avoid use in patients with severe immunosuppression: contraindicated in those with profound immune deficits. - Use with caution in patients with pre‑existing cardiac disease: monitor cardiac status. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may affect safety or efficacy. Major Interactions (Avoid): - Concurrent use with other immunomodulators: increased risk of uncontrolled immune activation. - Live vaccines: may cause severe infection due to immune stimulation. - Cytotoxic chemotherapy administered simultaneously: may enhance toxicity. Moderate Interactions (Monitor Closely): - Corticosteroids: may diminish therapeutic immune response. - Antihistamines: could mask early signs of infusion reactions. - Drugs affecting fluid balance: monitor for exacerbated hypotension or edema.